MedPage Today -- ORLANDO, June 4 -- Neoadjuvant chemotherapy demonstrated a small survival advantage over surgery alone for early-stage non-small cell lung cancer (NSCLC) and was better tolerated than adjuvant chemotherapy, researchers found.
